Overview
Genetic medicines firm's net loss for 2025 was $45.5 mln, smaller than $64.8 mln loss in 2024
Company advancing upliFT-D study for frontotemporal dementia
Cash runway expected through Q1 2027
Outlook
Passage Bio expects interim safety data from upliFT-D study in 1H 2026
Company aims to declare Huntington's disease clinical candidate in 2H 2026
Passage Bio has cash runway through 1Q 2027
Result Drivers
CLINICAL PROGRESS - Passage Bio advanced its upliFT-D study by enrolling first FTD-GRN patients in Cohort 3 and treating first FTD-C9orf72 patient in Cohort 4
HUNTINGTON'S PROGRAM - Co advancing preclinical program for Huntington’s disease with clinical candidate selection expected in 2H 2026
Company press release: ID:nGNX2PqQgm
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
FY Net Income | -$45.52 mln | ||
FY Income From Operations | -$49.30 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Passage Bio Inc is $32.00, about 264.5% above its March 2 closing price of $8.78
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)